Weight loss & body composition
Peptides for Weight Loss in Idaho
Peptides for weight loss fall into two very different groups. FDA-approved GLP-1 medications, semaglutide and tirzepatide, are backed by large randomized trials showing roughly 15–22% average body-weight loss, while off-label research peptides such as tesamorelin, AOD-9604 and MOTS-c have a smaller, still-growing body of human research and no FDA approval for weight loss, even as patients report changes in body composition and energy. Hormones + Weight Loss builds its nurse-practitioner-led weight-loss programs around the proven GLP-1 category at our Meridian, Twin Falls and Lewiston clinics, with Boise-area patients seen in Meridian.
The four kinds of “weight-loss peptides”
FDA-approved for chronic weight management
GLP-1 medications: semaglutide & tirzepatide
These are the peptides with proof. Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management and were tested in the large STEP and SURMOUNT trial programs. They work by slowing digestion, reducing appetite and improving blood-sugar regulation, and they are the foundation of our medically supervised weight-loss program.
Tesamorelin FDA-approved for HIV-related visceral fat only; others not approved
Growth-hormone secretagogues
Tesamorelin, sermorelin and CJC-1295/ipamorelin prompt the body to release its own growth hormone. They are discussed for body composition, visceral fat and lean mass rather than total weight loss, and patients using them often report changes in sleep quality and body composition, though the human research base in otherwise healthy adults is still smaller than the GLP-1 category. Tesamorelin is FDA-approved only for excess abdominal fat in people with HIV; the others are not FDA-approved for any use.
Emerging research; used alongside a supervised plan
Metabolic research peptides
MOTS-c is a mitochondrial-derived peptide studied for metabolic signaling, with animal research leading the way and human interest, including patient-reported energy and body-composition changes, running ahead of the published trial data. AOD-9604 is a fragment of growth hormone whose early-2000s obesity trials showed mixed results, and newer research has brought renewed interest in the compound. Neither is FDA-approved, and neither should be mistaken for a weight-loss treatment.
In clinical trials only; not available
Investigational: retatrutide
Retatrutide is a triple-agonist (GLP-1, GIP and glucagon receptors) still in phase 3 clinical trials. Early results have drawn a lot of attention, but there is no approved product, it is not on any compounding list, and anything sold under that name outside a trial is unregulated. We do not offer it and will update this page if its status changes.
GLP-1 medications vs. other weight-loss peptides
| Factor | GLP-1 medications | Other peptides |
|---|---|---|
| FDA status | FDA-approved for chronic weight management (Wegovy, Zepbound) | Not FDA-approved for weight loss; tesamorelin approved only for HIV-associated lipodystrophy; retatrutide investigational |
| Evidence | Large randomized controlled trials (STEP, SURMOUNT) with thousands of participants | Smaller studies and animal data, plus patient-reported results; no large human trial shows meaningful weight loss |
| Typical weight loss in trials | About 15% over 68 weeks (semaglutide); 16–22.5% over 72 weeks depending on dose (tirzepatide) | No comparable data; effects reported are on visceral fat or lean mass, not total weight |
| Sourcing | Brand-name pharmaceutical products, or compounded versions through licensed pharmacies where rules allow | Compounded through licensed pharmacies only where eligible; widely sold online as unregulated research chemicals |
| Cost | Priced separately as a supervised program; quoted after your consultation | Inside our clinic-wide range of about $100 to $1,000 or more, depending on the peptide and quantity |
| Best for | Adults whose primary goal is meaningful, sustained weight loss under clinical supervision | Selective, off-label body-composition goals after the evidence and unknowns have been discussed |
How our peptide-supported weight-loss program works
Consultation and labs
Your first visit is a full health history with a nurse practitioner plus lab work: metabolic markers, thyroid, and hormone levels that influence weight. This is the baseline everything else is measured against.
Candidacy review
We screen for contraindications, prior medications, gallbladder and pancreatic history, and hormone imbalances that would undercut results. Not everyone is a candidate for GLP-1 therapy, and we say so when that is the case.
GLP-1 selection and titration
If you qualify, your nurse practitioner chooses between semaglutide and tirzepatide based on your labs, goals and tolerance, then increases the dose gradually to limit side effects. Medication is sourced only through licensed pharmacies.
Body-composition tracking
Progress is measured on the InBody 570, not just a bathroom scale, so we can see whether you are losing fat and keeping muscle. Nutrition and protein guidance are adjusted from those scans.
Follow-up and maintenance
Regular check-ins manage side effects, adjust dosing and plan how you will hold your results. Other peptides are considered only when the evidence and current compounding rules support them, and only as an addition to a working program.
What results actually look like
The honest benchmark for GLP-1 weight loss comes from the trials themselves. In the STEP program, adults taking semaglutide lost about 15% of their body weight over roughly 68 weeks. In SURMOUNT-1, tirzepatide produced 16.0%, 21.4% and 22.5% average loss at its three dose levels over 72 weeks, against 2.4% for placebo.
A head-to-head trial, SURMOUNT-5, compared the two directly and found 20.2% average weight loss with tirzepatide versus 13.7% with semaglutide at 72 weeks. That is why tirzepatide is often the first choice when it is tolerated and available, but semaglutide remains a strong, well-studied option.
Results vary. These numbers come from controlled trials with steady follow-up, and individual outcomes depend on starting weight, adherence, diet, activity, hormone status and how your body responds. Weight loss is never guaranteed, and the program around the medication, labs, body-composition tracking and follow-up, is what turns a prescription into a result you can keep.
What it costs
At Hormones + Weight Loss, peptide pricing ranges from about $100 to $1,000 or more depending on the peptide and the quantity ordered, and GLP-1 weight-loss programs are priced separately as a supervised program. Your exact cost is quoted after your consultation and labs, and our peptide therapy cost guide explains what moves the number.
Read the peptide therapy cost guideWant the deeper comparison? Semaglutide vs. tirzepatide vs. retatrutide and our guide to what actually works.
Peptides for Weight Loss FAQs
FDA-approved GLP-1 medications are considered safe when prescribed and monitored by a clinician; common side effects are nausea and constipation, with rarer risks like pancreatitis. Other weight-loss peptides carry more uncertainty because long-term human data are limited. The biggest safety risk is unregulated online product, which the FDA has warned about repeatedly.
Based on published trials, tirzepatide produced the largest average weight loss (16–22.5% over 72 weeks), with semaglutide close behind at about 15%. No other peptide has comparable evidence. The best choice for you depends on your labs, health history, tolerance and availability, which is what your nurse practitioner reviews at consultation.
Ozempic is itself a peptide, semaglutide, approved for diabetes and used off-label for weight; Wegovy is the same molecule approved for weight management. Research peptides marketed as alternatives have not shown comparable weight loss in any large trial. If weight loss is the goal, GLP-1 therapy is the evidence-backed category.
In clinical trials, semaglutide averaged roughly 15% body-weight loss over 68 weeks and tirzepatide 16–22.5% over 72 weeks depending on dose. Individual results vary with adherence, starting weight and hormone status, and are not guaranteed. Non-GLP-1 peptides have no trial data showing meaningful weight loss.
GLP-1 side effects are mostly digestive: nausea, constipation, diarrhea and reduced appetite, usually easing as the dose settles. Less common risks include gallbladder problems and pancreatitis, which is why we run labs and follow up regularly. Growth-hormone peptides can cause water retention, joint aches and blood-sugar changes.
Peptide therapy at Hormones + Weight Loss ranges from about $100 to $1,000 or more depending on the peptide and quantity ordered, and GLP-1 weight-loss programs are priced separately as a supervised program that includes labs, body-composition tracking and follow-up. Your exact cost is quoted after your consultation.
Hormones + Weight Loss offers nurse-practitioner-led weight-loss programs at clinics in Meridian, Twin Falls and Lewiston, Idaho. Boise-area patients are seen at our Meridian clinic. Every program starts with a consultation and labs to confirm you are a candidate for GLP-1 therapy.
Peptide-supported weight loss near you
Consultations at all three clinics. Boise-area patients are seen at our Meridian clinic, minutes off Eagle Road and I-84.
Meridian
2572 N Stokesberry Pl #300
Meridian, ID 83646
Mon–Fri 8am–6pm
Twin Falls
496 Shoup Ave West Ste E
Twin Falls, ID 83301
Mon–Thu 8am–6pm
Lewiston
1630 23rd Ave Ste 1201A
Lewiston, ID 83501
Mon–Wed 8am–6pm
Educational content only. It does not replace an evaluation by a licensed clinician. Whether a peptide fits you is decided at your consultation.
Find out which option fits you
A consultation and labs come first. Then a nurse practitioner builds a plan around the medication with real evidence behind it.